The first B-RAF inhibitor studied in melanoma clinical trials was Sorafenib (Nexavar), a multi-kinase inhibitor targeting RAF, VEGFR, and other receptor tyrosine kinases (RTKs) [28]. Here, BRAF is linked to melanoma.